A patient I’ll call Rachel, a 42-year-old elementary school teacher in suburban Atlanta, joined a telehealth semaglutide program last fall after her insurance denied Wegovy coverage for the third time. She’d done her homework. She had PubMed abstracts printed in a folder. But when her first vial of compounded semaglutide arrived, she stared at it for twenty minutes because the concentration on the label didn’t match the dosing table she’d found on Reddit, and the volume she was supposed to draw up seemed impossibly small. She texted me a photo of the syringe markings. “Am I doing this right?”
That gap between understanding the drug intellectually and actually using it correctly is where most confusion lives. This article is meant to close it.
In short, compounded semaglutide follows a five-step weekly titration modeled on the STEP trials. You start at 0.25 mg, hold for four weeks, then climb through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each held for four weeks. The full ramp takes sixteen to seventeen weeks. Any step can be paused or extended if you’re not tolerating it well. And not everyone needs to reach 2.4 mg.
Why the Slow Climb Exists
The titration schedule is not red tape. It’s protective.
GLP-1 receptor agonists slow gastric emptying and act on appetite-regulating circuits in the hypothalamus. Both effects are dose-dependent. Patients who jump ahead on the dose schedule are more likely to hit a wall of nausea, vomiting, or diarrhea severe enough to quit the medication entirely. And quitting during early titration is, statistically, the most common point of discontinuation.
Think of it like altitude acclimatization. You could drive straight to the summit of Pikes Peak, but a meaningful number of people would get altitude sickness and turn around. The titration schedule is the equivalent of spending a night at base camp.
The STEP-1 trial, the landmark study, randomized 1,961 adults with overweight or obesity (without diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). But critically, every participant in that trial went through the same titration schedule. The impressive results were built on that foundation.
STEP-3 layered on intensive behavioral therapy and saw directionally larger effects. STEP-5 extended follow-up to 104 weeks and confirmed sustained weight reduction. STEP-2 focused on patients with type 2 diabetes. The SUSTAIN program, which preceded STEP, established semaglutide’s glycemic and cardiovascular profile at the diabetes-dose range (0.5 mg and 1.0 mg weekly, with a 2.0 mg dose added in SUSTAIN FORTE). SUSTAIN-6 reported a reduction in major adverse cardiovascular events in a high-risk diabetes population (Marso SP et al.).
The boring truth from all of this data: the dose-response curve for weight loss and glycemic improvement is graded, and so is the side-effect curve. Higher doses work better and cause more GI trouble. The titration schedule is how you thread that needle.
The Actual Numbers, Step by Step
Here’s the standard schedule, mirrored from the Wegovy label and used by most compounded programs:
- Weeks 1 through 4: 0.25 mg weekly
- Weeks 5 through 8: 0.5 mg weekly
- Weeks 9 through 12: 1.0 mg weekly
- Weeks 13 through 16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (maintenance)
One thing that trips people up, especially Rachel’s version of the problem: the dose that matters is the milligram dose, not the volume in the syringe. Compounding pharmacies produce semaglutide at different concentrations. A vial at 5 mg/mL will require a different injection volume than a vial at 2.5 mg/mL for the exact same milligram dose. If you’re switching between programs or pharmacies, confirm the milligram dose at each step. Don’t assume the syringe volume stays the same.
Three practical details that come up constantly:
Injection day consistency matters more than time of day. Pick a day (Tuesday, Saturday, whatever fits your life) and stick with it. Weekly consistency supports the steady-state plasma concentration that gives semaglutide its reliable effect. Bouncing between Monday and Thursday is not the same as picking one and holding it.
Missed doses have a 48-hour rule of thumb. If you realize within about 48 hours of your scheduled day, take the dose when you remember and return to your regular day the following week. If more than 48 hours have passed, skip it and resume on the next scheduled day. Don’t double up.
Don’t freelance your dose adjustments. Communicate changes to your prescribing program. Self-adjusting based on what you read in a Facebook group is a reliable way to end up nauseated or, worse, to lose your prescriber’s willingness to work with you.
Side Effects: What’s Common and What’s Concerning
Gastrointestinal side effects dominate. Nausea, diarrhea, constipation, vomiting, and abdominal discomfort were reported consistently across the STEP and SUSTAIN programs and match real-world experience. Most events are mild to moderate, peak in the first eight to twelve weeks, and resolve either spontaneously or with a temporary dose hold.
Here’s my genuinely opinionated take: the single biggest mistake patients make is powering through significant nausea to stay on schedule rather than holding at the current dose for an extra four weeks. The titration schedule is a minimum pace, not a deadline. Staying at 0.5 mg for eight weeks instead of four is a perfectly reasonable clinical decision. Quitting the drug entirely because you white-knuckled through 1.0 mg and vomited for a week is not.
Less common but important:
- Gallbladder events, especially in patients losing weight rapidly. Right upper quadrant pain after meals or jaundice warrants evaluation.
- Acute pancreatitis, rare but real. Severe, persistent abdominal pain radiating to the back (particularly with fever) needs immediate medical attention.
- Thyroid C-cell tumor signal, based on rodent data that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning, and semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
Hypoglycemia is uncommon in non-diabetic patients on semaglutide alone because its insulin-stimulating effect is glucose-dependent (it works when blood sugar is elevated, not when it’s normal). The risk rises when semaglutide is combined with insulin or sulfonylureas, which is a diabetes-specific concern that requires adjusting the other medications.
The Brand vs. Compounded Question
Brand-name Wegovy and Ozempic carry US list prices above $1,300/month, with cash-pay rates at most retail pharmacies in the $1,000 to $1,400 range. Insurance coverage for weight management is inconsistent at best. This is the core reason compounded semaglutide programs exist.
HealthRX, a LegitScript-certified telehealth program, prices its compounded semaglutide at $179.99 to $279.99 per month depending on dose, available in 44 states. That price gap is not a trick. It reflects a different production and regulatory pathway, not a different molecule.
The distinction worth understanding: brand-name finished products went through registrational trials, carry FDA-approved labels, and are manufactured at industrial scale by Novo Nordisk. Compounded preparations contain the same active ingredient, are prepared by state-licensed or 503A compounding pharmacies for individual patients, and are not FDA-approved as finished products. Three practical implications follow from that:
- The STEP and SUSTAIN evidence base is built on the brand product. It informs expectations for compounded semaglutide but doesn’t directly extend to it.
- Manufacturing oversight differs. Compounding pharmacies are regulated by state boards of pharmacy (and, for 503B outsourcing facilities, by the FDA under a separate framework).
- Adverse-event surveillance is less systematic for compounded preparations.
None of this means compounded semaglutide is unsafe. It means the two pathways operate under different frameworks, and a good program will explain that difference before you enroll, not after.
For patients who want a more detailed walkthrough of the titration schedule, dose-adjustment decision points, and the clinical rationale behind each step, this compounded semaglutide dosing & protocols guide covers the questions that typically come up in an intake conversation. It’s not a substitute for talking to your prescriber. It’s the kind of reading that makes that conversation more efficient.
See also: Intelligent Home Systems
When You Should Actually Call Someone
Self-management has limits. These scenarios warrant direct contact with your prescribing program or a clinician:
- Severe, persistent abdominal pain, especially with radiation to the back or fever (rule out pancreatitis)
- Inability to keep down fluids for more than 24 hours, signs of dehydration, or persistent vomiting
- New gallbladder symptoms (post-meal right upper quadrant pain, jaundice)
- New or worsening reflux that doesn’t respond to meal-timing changes
- Mood changes, including new or worsening depression (raise this at your next follow-up, or sooner if it’s acute)
- Pregnancy, planned pregnancy, or breastfeeding (talk to your prescriber before the next dose)
- Personal or family history of medullary thyroid carcinoma or MEN2 that somehow wasn’t caught at intake (this is a contraindication; address it immediately)
- Hypoglycemic episodes if you’re on insulin, sulfonylureas, or other glucose-lowering agents (the concurrent medication likely needs adjustment)
- You’re on warfarin or another medication with a narrow therapeutic window (semaglutide’s effect on gastric emptying can alter absorption of other drugs)
Frequently Asked Questions
Can I skip a titration step?
Skipping steps is not standard. The schedule exists to let your GI tract and appetite-regulation circuits adapt. Skipping increases the likelihood of side effects severe enough to make you stop the medication.
What if I miss a weekly dose?
If it’s within roughly 48 hours of your scheduled day, take it when you remember and return to your regular schedule the following week. If more than 48 hours have passed, skip the missed dose and take the next one on your regular day. Your program will have specific guidance; follow theirs.
How do I know when to step up?
Tolerability is the signal. If you’ve completed four weeks at your current dose and you’re not dealing with significant GI symptoms, you’re generally a candidate to move up. If nausea or other side effects are still active, hold the current dose for another four weeks.
Is 2.4 mg the target for everyone?
No. Some patients reach clinically meaningful results at 1.0 mg or 1.7 mg and stay there. The target dose is wherever you’re getting the intended effect with acceptable tolerability.
How long should I stay on the maintenance dose?
This is individualized. The STEP-5 dataset supports continued use for at least two years, and clinical experience extends further. It’s a conversation with your prescriber, not a fixed endpoint.
Does the injection site matter?
Abdomen, thigh, and upper arm are the standard sites. Rotate between them. Consistency in the milligram dose matters far more than injection location.
Can I use HSA or FSA funds?
It depends on your plan and the documentation the program provides. Confirm the invoicing format with the program before enrollment so you’re not retroactively trying to get reimbursed with insufficient paperwork.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
